KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis
← catalyst calendarSponsored by Kyverna Therapeutics (industry) · KYTX — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
3actual
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-06 | actual | When the study began enrolling |
| Primary completion | Mar 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-05-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Systemic Sclerosis
- Systemic Sclerosis - Diffuse Cutaneous
- Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria
Interventions
- Biological: KYV-101
- Drug: Standard lymphodepletion regimen — also filed as Cyclophosphamide, Fludarabine
Primary outcomes
what the primary-completion date above is the date OFIncidence of adverse events and laboratory abnormalities (Phase 1)
measured Up to 2 years
Frequency of Dose-Limiting Toxicities (DLTs) at each dose level (Phase 1)
measured Up to 2 years
To evaluate efficacy of KYV-101(Phase 2)
measured 52 weeks
Publications
- PMID 29669578 — cited as background
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · KYTX's whole pipeline · Catalyst calendar · Every registered study · What changed